Skidude said:
sunnygirl said:
Hey everyone! I began reta in may, and it's july now. The scale has moved just 4 pounds. I want to stay optimistic about this journey, but 4lbs seems low for 2 months. Should I be considering a switch to triz already, or is it too soon and I should stick with it longer?
Here's my dosing so far, taken once a week:
first dose: 0.5 mg
Second dose, 0.5 mg
Third dose, 1.0 mg
Fourth dose, 1.0 mg
Fifth dose, 1.0 mg
Sixth dose, 1.5 mg
Seventh dose, 1.5 mg
Not everyone reacts the same way — some people get a stronger response than others.
Have you noticed any unwanted side effects?
Like I mentioned earlier, your total body weight is relevant here — do you have a high BMI?
Your starting dose was quite low, and that could be contributing to the problem.
The usual principle is to begin at a level that produces weight loss while keeping side effects to a minimum; it's possible you simply need to titrate up..
About TRIUMPH-1 and the TRIUMPH clinical trial program
TRIUMPH‑1 (NCT05929066) is a Phase 3, 80‑week, randomized, double‑blind, placebo‑controlled master trial comparing the efficacy and safety of retatrutide with placebo in adults with obesity or overweight. TRIUMPH-1 included a master trial for obesity and two basket trials for knee osteoarthritis pain or moderate-to-severe obstructive sleep apnea. The study randomized 2,339 participants in a 1:1:1:1 ratio to receive either retatrutide 4 mg, 9 mg, 12 mg, or placebo.
Participants randomized to retatrutide initiated treatment with 2 mg once weekly and increased the dose in a step-wise approach every four weeks until reaching the target dose of 4 mg (via one step at 2 mg), 9 mg (via steps at 2 mg, 4 mg and 6 mg) or 12 mg (via steps at 2 mg, 4 mg, 6 mg and 9 mg). TRIUMPH-1 included a pre-specified extension period of 104 weeks. The extension period enrolled 532 participants with BMI ≥35 at week 0 who completed the main 80-week study and tolerated their assigned dose of medication. Participants received retatrutide once weekly for an additional 24 weeks, including a blinded escalation to maximum tolerated dose (9 mg or 12 mg). Data described in this press release refer to the master trial and extension period; analyses of the two basket trials for knee osteoarthritis pain and moderate-to-severe obstructive sleep apnea will be released subsequently.
If you take a few moments and read this it may help
https://pep-pedia.org/peptides/retatrutide